AGL 40.15 Increased By ▲ 0.15 (0.38%)
AIRLINK 130.30 Increased By ▲ 0.77 (0.59%)
BOP 6.80 Increased By ▲ 0.12 (1.8%)
CNERGY 4.60 Decreased By ▼ -0.03 (-0.65%)
DCL 9.05 Increased By ▲ 0.11 (1.23%)
DFML 43.30 Increased By ▲ 1.61 (3.86%)
DGKC 84.20 Increased By ▲ 0.43 (0.51%)
FCCL 33.00 Increased By ▲ 0.23 (0.7%)
FFBL 77.90 Increased By ▲ 2.43 (3.22%)
FFL 11.90 Increased By ▲ 0.43 (3.75%)
HUBC 110.86 Increased By ▲ 0.31 (0.28%)
HUMNL 14.55 Decreased By ▼ -0.01 (-0.07%)
KEL 5.54 Increased By ▲ 0.15 (2.78%)
KOSM 8.22 Decreased By ▼ -0.18 (-2.14%)
MLCF 39.80 Increased By ▲ 0.01 (0.03%)
NBP 60.85 Increased By ▲ 0.56 (0.93%)
OGDC 199.50 Decreased By ▼ -0.16 (-0.08%)
PAEL 26.66 Increased By ▲ 0.01 (0.04%)
PIBTL 7.80 Increased By ▲ 0.14 (1.83%)
PPL 159.52 Increased By ▲ 1.60 (1.01%)
PRL 26.76 Increased By ▲ 0.03 (0.11%)
PTC 18.85 Increased By ▲ 0.39 (2.11%)
SEARL 83.15 Increased By ▲ 0.71 (0.86%)
TELE 8.18 Decreased By ▼ -0.13 (-1.56%)
TOMCL 34.50 Decreased By ▼ -0.01 (-0.03%)
TPLP 9.09 Increased By ▲ 0.03 (0.33%)
TREET 17.11 Decreased By ▼ -0.36 (-2.06%)
TRG 59.97 Decreased By ▼ -1.35 (-2.2%)
UNITY 27.60 Increased By ▲ 0.17 (0.62%)
WTL 1.42 Increased By ▲ 0.04 (2.9%)
BR100 10,534 Increased By 127 (1.22%)
BR30 31,898 Increased By 185 (0.58%)
KSE100 98,147 Increased By 818.7 (0.84%)
KSE30 30,514 Increased By 321.6 (1.07%)

Abbott Laboratories' first-quarter profit and sales beat analysts' estimates on Wednesday but some investors were disappointed as the healthcare company maintained its full-year profit forecast. The company's shares were down about 2 percent in early trading.
"It's all about the expectations," Evercore ISI analyst Vijay Kumar said, adding that some investors may have been expecting the company to raise its full-year earnings forecast. The company reiterated its FY 2018 forecast of adjusted earnings from continuing operation between $2.80 to $2.90 per share.
Abbott's first-quarter results were mainly helped by launches of new medical devices and a turnaround in its business that sells baby and adult nutritional supplements. Sales in the nutrition business, known for brands such as Similac and PediaSure, have been hemmed in since mid-2016, when China made it mandatory for manufacturers to re-register baby formulae with the government.
Quarterly sales at the unit increased 4.7 percent on an organic basis to $1.76 billion, above consensus estimates of $1.72 million, compiled by Cowen. The company reported net earnings of $418 million, or 23 cents per share, in the quarter ended March 31, compared to $419 million, or 24 cents per share, a year earlier.
Profit from Abbott's medical device business - its largest division - continued to benefit from its $25 billion purchase of St. Jude Medical, and from new device launches. Sales for the unit rose 14.6 percent to $2.74 billion in the quarter. "With the integration of Alere and St. Jude Medical well underway, debt repayment progressing, and a slew of new product launches already making a splash, Abbott continues to impress in 2018," BMO Capital Markets analyst Joanne Wuensch said.
Net sales rose to $7.39 billion from $6.34 billion. Excluding items, Abbott reported a profit of 59 cents per share. Analysts on average had expected profit of 58 cents per share on revenue of $7.29 billion, according to Thomson Reuters I/B/E/S.

Copyright Reuters, 2018

Comments

Comments are closed.